Abstract:Background Anticoagulation is the mainstay for stroke prevention in patients with atrial fibrillation, but concerns about bleeding inhibit its use in residents of long‐term care facilities. Risk‐profiling algorithms using comorbid disease information (eg, CHADS 2 and ATRIA [Anticoagulation and Risk Factors in Atrial Fibrillation]) have been available for years. In the long‐term care setting, however, providers and residents may place more value on geriatric conditions such as mobility impairment, activities of daily living dependency, cognitive impairment, low body mass index, weight loss, and fall history. Methods and Results Using a retrospective cohort design, we measured the association between geriatric conditions and anticoagulation use and type. After merging nursing home assessments containing information about geriatric conditions (Minimum Data Set 2015) with Medicare Part A 2014 to 2015 claims and prescription claims (Medicare Part D) 2015 to 2016, we identified 228 741 residents with atrial fibrillation and elevated stroke risk (CHA 2 DS 2 ‐VASc score ≥2) for our main analysis. Recent fall, activities of daily living dependency, moderate and severe cognitive impairment, low body mass index, and unintentional weight loss were all associated with lower anticoagulation use even after adjustment for multiple predictors of stroke and bleeding (odds ratios ranging from 0.51 to 0.91). Residents with recent fall, low body mass index, and unintentional weight loss were more likely to be using a direct oral anticoagulant, although the magnitude of this effect was smaller. Conclusions Geriatric conditions were associated with lower anticoagulation use. Preventing stroke in these residents with potential for further physical and cognitive impairment would appear to be of paramount significance, although the net benefit of anticoagulation in these individuals warrants further research. Nonstandard Abbreviations and Acronyms ATRIA Anticoagulation and Risk Factors in Atrial Fibrillation DOAC direct oral anticoagulant LTC long‐term care MDS minimum data set Clinical Perspective What Is New? Geriatric conditions, including mobility impairment, activities of daily living dependency, cognitive impairment, low body mass index, weight loss, and fall history, are associated with lower anticoagulation use in long‐term care residents with atrial fibrillation. What Are the Clinical Implications? Professional societies and policymakers should provide greater guidance to clinicians treating these residents about which residents with geriatric conditions should receive anticoagulation. Atrial fibrillation (AF) affects 5.2 million Americans and is particularly prevalent in long‐term care (LTC) facilities, with estimates ranging from 7.5% to 17%. 1 Anticoagulation is the mainstay for stroke prevention in residents of LTC facilities, but concerns about bleeding inhibit the adoption of its use even in cases in which the benefit of treatment outweighs the risk. The advent of direct oral anticoagulants (DOACs) and issuance of the American College of Cardiology and American Heart Association recommendation of anticoagulation in low‐ to moderate‐risk patients (CHA 2 DS 2‐ VASc ≥2) has reduced the gap, but >40% of eligible patients remain at elevated risk of stroke. 2 To understand better the gap in anticoagulation use in the LTC population requires identification of which patient‐level factors predict anticoagulation use in general and DOAC use in particular. Although the original CHADS 2 and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) stroke and bleeding risk scoring algorithms 3 , 4 have been available for many years, in the LTC setting providers and residents may place more value on other unique factors. These include many of the conditions identified through a comprehensive geriatric assessment (hereafter called geriatric c -Abstract Truncated-

Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation

Clinical study of cerebral infarction prevention with warfarin in nonvalvular atrial fibrillation

Randomized Study of Efficiency and Safety of Antithrombotic Therapy with Warfarin in Nonvalvular Atrial Fibrillation

Stroke prevention in atrial fibrillation: comparison of recent international guidelines

Antithrombotic therapy in patients with atrial fibrillation after myocardial infarction and percutaneous coronary intervention

Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized Trials

Stratified clinical study of antithrombotic therapy in patients with atrial fibrillation

A Retrospective Study on Patients with Stroke and Non-Rheumatic Atrial Fibrillation Treated with Anticoagulation

The Chads(2) And Cha(2)Ds(2)-Vasc Scores For Predicting Ischemic Stroke Among East Asian Patients With Atrial Fibrillation: A Systemic Review And Meta-Analysis

The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis

Managing anticoagulation for atrial fibrillation: current issues and future strategies

Meta-Analysis of CHADS2 Versus CHA2DS2-VASc for Predicting Stroke and Thromboembolism in Atrial Fibrillation Patients Independent of Anticoagulation

The Anticoagulation Therapy Dilemma

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage

Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients

Geriatric Conditions Are Associated With Decreased Anticoagulation Use in Long-Term Care Residents With Atrial Fibrillation.

CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis.

Refinement of Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA2DS2‐VASc Score of 1

Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation

Aspects of anticoagulant therapy in patients with atrial fibrillation in the light of updated guidelines of the European society of cardiology 2020: the position of dabigatran